|
|
 Previous Article | Table of Contents | Next Article 
Soluble forms of the interleukin-6 signal-transducing receptor component
gp130 in human serum possessing a potential to inhibit signals through
membrane-anchored gp130
M Narazaki, K Yasukawa, T Saito, Y Ohsugi, H Fukui, Y Koishihara, GD Yancopoulos, T Taga and T Kishimoto
Division of Immunology, Osaka University, Japan.
The interleukin-6 (IL-6) signal is transduced through membrane-anchored
gp130, which is associated with IL-6 receptor (IL-6R) in the presence of
IL-6. Soluble forms of gp130 (sgp130) with molecular weights of 90 and 110
Kd were found in human serum. In the presence of recombinant IL- 6 (rIL-6),
serum sgp130 were capable of associating with serum sIL-6R. By the sandwich
enzyme-linked immunosorbent assay, healthy human sera was shown to contain
390 +/- 72 ng/mL of sgp130. A mouse pro-B-cell line-derived transfectant,
BAF-130, expressing human gp130 was used to examine the function of serum
sgp130. When supplemented with rIL-6, human serum induced DNA synthesis in
BAF-130 cells, whereas the serum deprived of sIL-6R did not. In contrast,
the DNA synthesis induced in BAF-130 cells by rIL-6-supplemented serum was
increased when the serum was deprived of sgp130. These results indicated
that serum sgp130 could negatively regulate the IL-6 signal. Recently,
gp130 has been shown to be involved in the signaling processes of
oncostatin M, leukemia inhibitory factor, and ciliary neurotropic factor,
in addition to those of IL-6. Recombinant sgp130 showed inhibitory effect
on the biologic function of such cytokines. This work implies physiologic
roles of naturally produced serum sgp130 in modulating signals through
gp130.
Volume 82,
Issue 4,
pp. 1120-1126,
08/15/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Tenhumberg, G. H. Waetzig, A. Chalaris, B. Rabe, D. Seegert, J. Scheller, S. Rose-John, and J. Grotzinger
Structure-guided Optimization of the Interleukin-6 Trans-signaling Antagonist sgp130
J. Biol. Chem.,
October 3, 2008;
283(40):
27200 - 27207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Tanaka, N. Tanaka, Y. Saeki, K. Tanaka, M. Murakami, T. Hirano, N. Ishii, and K. Sugamura
c-Cbl-Dependent Monoubiquitination and Lysosomal Degradation of gp130
Mol. Cell. Biol.,
August 1, 2008;
28(15):
4805 - 4818.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Metz, M. Wiesinger, M. Vogt, H. Lauks, G. Schmalzing, P. C. Heinrich, and G. Muller-Newen
Characterization of the Interleukin (IL)-6 Inhibitor IL-6-RFP: FUSED RECEPTOR DOMAINS ACT AS HIGH AFFINITY CYTOKINE-BINDING PROTEINS
J. Biol. Chem.,
January 12, 2007;
282(2):
1238 - 1248.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Diveu, E. Venereau, J. Froger, E. Ravon, L. Grimaud, F. Rousseau, S. Chevalier, and H. Gascan
Molecular and Functional Characterization of a Soluble Form of Oncostatin M/Interleukin-31 Shared Receptor
J. Biol. Chem.,
December 1, 2006;
281(48):
36673 - 36682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Maggio, J. M. Guralnik, D. L. Longo, and L. Ferrucci
Interleukin-6 in aging and chronic disease: a magnificent pathway.
J. Gerontol. A Biol. Sci. Med. Sci.,
June 1, 2006;
61(6):
575 - 584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Song and H. Lim
Evidence for heterodimeric association of leukemia inhibitory factor (LIF) receptor and gp130 in the mouse uterus for LIF signaling during blastocyst implantation
Reproduction,
February 1, 2006;
131(2):
341 - 349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T Gustot, A Lemmers, E Louis, C Nicaise, E Quertinmont, J Belaiche, S Roland, A Van Gossum, J Deviere, and D Franchimont
Profile of soluble cytokine receptors in Crohn's disease
Gut,
April 1, 2005;
54(4):
488 - 495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Memoli, G. Grandaliano, M. Soccio, L. Postiglione, B. Guida, V. Bisesti, P. Esposito, A. Procino, D. Marrone, A. Michael, et al.
In Vivo Modulation of Soluble "Antagonistic" IL-6 Receptor Synthesis and Release in ESRD
J. Am. Soc. Nephrol.,
April 1, 2005;
16(4):
1099 - 1107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Classen-Linke, G. Muller-Newen, P.C. Heinrich, H.M. Beier, and U. von Rango
The cytokine receptor gp130 and its soluble form are under hormonal control in human endometrium and decidua
Mol. Hum. Reprod.,
July 1, 2004;
10(7):
495 - 504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Brown, N. Hu, and J. C.-G. Hombria
Novel level of signalling control in the JAK/STAT pathway revealed by in situ visualisation of protein-protein interaction during Drosophila development
Development,
July 15, 2003;
130(14):
3077 - 3084.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ancey, A. Kuster, S. Haan, A. Herrmann, P. C. Heinrich, and G. Muller-Newen
A Fusion Protein of the gp130 and Interleukin-6Ralpha Ligand-binding Domains Acts as a Potent Interleukin-6 Inhibitor
J. Biol. Chem.,
May 2, 2003;
278(19):
16968 - 16972.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Von der Thusen, J. Kuiper, T. J. C. Van Berkel, and E. A. L. Biessen
Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential
Pharmacol. Rev.,
March 1, 2003;
55(1):
133 - 166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Aoki, G. M. Feldman, and G. Tosato
Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma
Blood,
February 15, 2003;
101(4):
1535 - 1542.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Varghese, R. L. Moritz, M.-Z. Lou, A. van Donkelaar, H. Ji, N. Ivancic, K. M. Branson, N. E. Hall, and R. J. Simpson
Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain
PNAS,
December 10, 2002;
99(25):
15959 - 15964.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. A. Sherwin, S. K. Smith, A. Wilson, and A. M. Sharkey
Soluble gp130 is Up-Regulated in the Implantation Window and Shows Altered Secretion in Patients with Primary Unexplained Infertility
J. Clin. Endocrinol. Metab.,
August 1, 2002;
87(8):
3953 - 3960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Aoki, M. Narazaki, T. Kishimoto, and G. Tosato
Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus
Blood,
November 15, 2001;
98(10):
3042 - 3049.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. JONES, S. HORIUCHI, N. TOPLEY, N. YAMAMOTO, and G. M. FULLER
The soluble interleukin 6 receptor: mechanisms of production and implications in disease
FASEB J,
January 1, 2001;
15(1):
43 - 58.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Mei{beta}ner, H. Blum, M. Schnare, M. Rollinghoff, and A. Gessner
A soluble form of the murine common {gamma} chain is present at high concentrations in vivo and suppresses cytokine signaling
Blood,
January 1, 2001;
97(1):
183 - 191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K L STREETZ, T LUEDDE, M P MANNS, and C TRAUTWEIN
Interleukin 6 and liver regeneration
Gut,
August 1, 2000;
47(2):
309 - 312.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Corbi, M. Rahmati, A. Delwail, D. Potreau, P. Menu, J. Wijdenes, and J.-C. Lecron
Circulating soluble gp130, soluble IL-6R, and IL-6 in patients undergoing cardiac surgery, with or without extracorporeal circulation
Eur. J. Cardiothorac. Surg.,
July 1, 2000;
18(1):
98 - 103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Auernhammer and S. Melmed
Leukemia-Inhibitory Factor--Neuroimmune Modulator of Endocrine Function
Endocr. Rev.,
June 1, 2000;
21(3):
313 - 345.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. C. Manolagas
Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis
Endocr. Rev.,
April 1, 2000;
21(2):
115 - 137.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N. Nishimoto, A. Ito, M. Ono, H. Tagoh, T. Matsumoto, T. Tomita, T. Ochi, and K. Yoshizaki
IL-6 inhibits the proliferation of fibroblastic synovial cells from rheumatoid arthritis patients in the presence of soluble IL-6 receptor
Int. Immunol.,
February 1, 2000;
12(2):
187 - 193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Sayani, F. A. Montero-Julian, V. Ranchin, J. M. Prevost, S. Flavetta, W. Zhu, R. C. Woodman, H. Brailly, and C. B. Brown
Identification of the soluble granulocyte-macrophage colony stimulating factor receptor protein in vivo
Blood,
January 15, 2000;
95(2):
461 - 469.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Le Meur, V. Lorgeot, J.-C. Aldigier, J. Wijdenes, C. Leroux-Robert, and V. Praloran
Whole blood production of monocytic cytokines (IL-1{beta}, IL-6, TNF-{alpha}, sIL-6R, IL-1Ra) in haemodialysed patients
Nephrol. Dial. Transplant.,
October 1, 1999;
14(10):
2420 - 2426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Cole, N. E. Hall, H. R. Treutlein, J. S. Eddes, G. E. Reid, R. L. Moritz, and R. J. Simpson
Disulfide Bond Structure and N-Glycosylation Sites of the Extracellular Domain of the Human Interleukin-6 Receptor
J. Biol. Chem.,
March 12, 1999;
274(11):
7207 - 7215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Muller-Newen, A. Kuster, U. Hemmann, R. Keul, U. Horsten, A. Martens, L. Graeve, J. Wijdenes, and P. C. Heinrich
Soluble IL-6 Receptor Potentiates the Antagonistic Activity of Soluble gp130 on IL-6 Responses
J. Immunol.,
December 1, 1998;
161(11):
6347 - 6355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Peters, A. M. Muller, and S. Rose-John
Interleukin-6 and Soluble Interleukin-6 Receptor: Direct Stimulation of gp130 and Hematopoiesis
Blood,
November 15, 1998;
92(10):
3495 - 3504.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. A. Adebanjo, B. S. Moonga, T. Yamate, L. Sun, C. Minkin, E. Abe, and M. Zaidi
Mode of Action of Interleukin-6 on Mature Osteoclasts. Novel Interactions with Extracellular Ca2+ Sensing in the Regulation of Osteoclastic Bone Resorption
J. Cell Biol.,
September 7, 1998;
142(5):
1347 - 1356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. C. A. Elson, P. Graber, C. Losberger, S. Herren, D. Gretener, L. N. Menoud, T. N. C. Wells, M. H. Kosco-Vilbois, and J.-F. Gauchat
Cytokine-Like Factor-1, a Novel Soluble Protein, Shares Homology with Members of the Cytokine Type I Receptor Family
J. Immunol.,
August 1, 1998;
161(3):
1371 - 1379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-G. Zhang, Y. Zhang, C. M. Owczarek, L. D. Ward, R. L. Moritz, R. J. Simpson, K. Yasukawa, and N. A. Nicola
Identification and Characterization of Two Distinct Truncated Forms of gp130 and a Soluble Form of Leukemia Inhibitory Factor Receptor alpha -Chain in Normal Human Urine and Plasma
J. Biol. Chem.,
April 24, 1998;
273(17):
10798 - 10805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. I. Ndubuisi, K. Patel, R. J. Rayanade, A. Mittelman, L. T. May, and P. B. Sehgal
Distinct Classes of Chaperoned IL-6 in Human Blood: Differential Immunological and Biological Availability
J. Immunol.,
January 1, 1998;
160(1):
494 - 501.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Franchimont, V. Gangji, D. Durant, and E. Canalis
Interleukin-6 with Its Soluble Receptor Enhances the Expression of Insulin-Like Growth Factor-I in Osteoblasts
Endocrinology,
December 1, 1997;
138(12):
5248 - 5255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Peters, P. Schirmacher, J. Goldschmitt, M. Odenthal, C. Peschel, E. Fattori, G. Ciliberto, H.-P. Dienes, K.-H. M. z. Buschenfelde, and S. Rose-John
Extramedullary Expansion of Hematopoietic Progenitor Cells in Interleukin (IL)-6-sIL-6R Double Transgenic Mice
J. Exp. Med.,
February 17, 1997;
185(4):
755 - 766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Hudson, A. B. Vernallis, and J. K. Heath
Characterization of the Receptor Binding Sites of Human Leukemia Inhibitory Factor and Creation of Antagonists
J. Biol. Chem.,
May 17, 1996;
271(20):
11971 - 11978.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Pennica, K. J. Shaw, T. A. Swanson, M. W. Moore, D. L. Shelton, K. A. Zioncheck, A. Rosenthal, T. Taga, N. F. Paoni, and W. I. Wood
Cardiotrophin-1
J. Biol. Chem.,
May 5, 1995;
270(18):
10915 - 10922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ehlers, F. D. de Hon, H. K. Bos, U. Horsten, Gün. Kurapkat, H. S. van De Leur, J. Grötzinger, A. Wollmer, J. P. J. Brakenhoff, and S. Rose-John
Combining Two Mutations of Human Interleukin-6 That Affect gp130 Activation Results in a Potent Interleukin-6 Receptor Antagonist on Human Myeloma Cells
J. Biol. Chem.,
April 7, 1995;
270(14):
8158 - 8163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Moritz, N. E. Hall, L. M. Connolly, and R. J. Simpson
Determination of the Disulfide Structure and N-Glycosylation Sites of the Extracellular Domain of the Human Signal Transducer gp130
J. Biol. Chem.,
March 9, 2001;
276(11):
8244 - 8253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
